We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Notes From The Beauty Contest’s Substack by ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $500.0 and $750.0 for Regeneron Pharmaceuticals, spanning the ...

Regeneron Pharmaceuticals (REGN) shares have shown steady gains over the past month, supported by the company’s consistent revenue and net income growth. Investors are keeping an eye on how Regeneron ...

Following FDA rejections, Regeneron and Scholar Rock are turning to other facilities to clear regulatory logjams created by ...

Dupixent shows stable positive dynamics and becomes the main asset, while sales of Eylea are under pressure. Regeneron still has a strong pipeline, but the focus is shifting toward oncology. Valuation ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective dropped by analysts at JPMorgan Chase & Co. from $1,100.00 to $1,000.00 in a report released on Monday,Benzinga ...

The Food and Drug Administration on Saturday granted an emergency use authorization for Regeneron’s Covid-19 antibody treatment, the experimental therapy given to President Donald Trump when he ...

"Regeneron and Tessera join forces to forge in vivo AATD gene therapy " was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.